Newron Pharmaceuticals
Italy - Bresso
Pharmaceutical4 H-1B visas (FY2023)Focus: Neurological Drugs
Newron Pharmaceuticals is a life sciences company focused on Neurological Drugs.
Neurology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
A Follow-up Study on Safety and Tolerability of Intracerebroventricular Administration of sNN0031 to
Parkinson's DiseaseClinical Trials (1)
NCT01807338A Follow-up Study on Safety and Tolerability of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease
N/APhase 1
Clinical Trials (1)
NCT01999803A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS
Phase 1NW-3509a
SchizophreniaClinical Trials (1)
NCT01955564A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
Phase 1Evenamide
HealthyClinical Trials (1)
NCT03446274An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects
Phase 1sNN0029 infusion solution
Amyotrophic Lateral SclerosisClinical Trials (1)
NCT02269436A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS
Phase 1sNN0031
Parkinson's DiseaseClinical Trials (1)
NCT01829867A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.
Phase 150mg safinamide
Renal ImpairmentClinical Trials (1)
NCT01374113Safinamide Renal Impairment Trial
Phase 1safinamide
Hepatic ImpairmentClinical Trials (1)
NCT01027169A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics
Phase 1Phase 1/2
Clinical Trials (1)
NCT00800501A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis
Phase 1/2Safinamide + Levodopa
Idiopathic Parkinson's DiseaseClinical Trials (1)
NCT01026428A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics
Phase 1/2sNN0031
Parkinson's DiseaseClinical Trials (1)
NCT00866502A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease
Phase 1/2i.c.v. infusion of sNN0031 by an Implanted infusion system
Parkinson's DiseaseClinical Trials (1)
NCT02408562Study on Tolerability of Repeat i.c.v. Administration of sNN0031 Infusion Solution in Patients With PD
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT01384162An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis
Phase 1/2Ralfinamide
Neuropathic PainClinical Trials (1)
NCT00736151Phase II Dose Titration Study in Patients With Neuropathic Pain
Phase 2Evenamide
SchizophreniaClinical Trials (1)
NCT04461119Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia
Phase 2Phase 2
Clinical Trials (1)
NCT01211587A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
Phase 2Safinamide
Parkinson DiseaseClinical Trials (1)
NCT01264861A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging
Phase 2NW-3509A
Chronic SchizophreniaClinical Trials (1)
NCT02624167A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
Phase 2Placebo
Parkinson's DiseaseClinical Trials (1)
NCT01113320Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects
Phase 2Sarizotan low dose
Rett SyndromeClinical Trials (1)
NCT02790034Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
Phase 2/3Safinamide
Parkinson's DiseaseClinical Trials (1)
NCT00642889Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)
Phase 3Evenamide 15 mg bid
Treatment-resistant SchizophreniaClinical Trials (1)
NCT07184619Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Phase 3Safinamide
Idiopathic Parkinson's DiseaseClinical Trials (1)
NCT00605683MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
Phase 3Safinamide
Parkinson's DiseaseClinical Trials (1)
NCT01187966Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease
Phase 3Safinamide
Parkinson's DiseaseClinical Trials (1)
NCT0128693518-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD
Phase 3Safinamide, MAO-B inhibitor
Idiopathic Parkinson's DiseaseClinical Trials (1)
NCT01028586MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)
Phase 3Safinimide 50-100 mg/day
Idiopathic Parkinson's DiseaseClinical Trials (1)
NCT00627640Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
Phase 3Safinamide
Idiopathic Parkinson's DiseaseClinical Trials (1)
NCT00643045Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Phase 3Safinamide
Parkinson's DiseaseClinical Trials (1)
NCT00865579Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients
Phase 3Ralfinamide
PainClinical Trials (1)
NCT01019824Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 1999
Portfolio: 30 clinical trials
H-1B (2023): 4 approvals
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
4
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub